vs
CSW INDUSTRIALS, INC.（CSW）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
CSW INDUSTRIALS, INC.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$233.0M vs $207.3M），CSW INDUSTRIALS, INC.净利率更高（4.4% vs -62.0%，领先66.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 20.3%），CSW INDUSTRIALS, INC.自由现金流更多（$22.7M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 5.1%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CSW vs RARE — 直观对比
营收规模更大
CSW
是对方的1.1倍
$207.3M
营收增速更快
RARE
高出5.6%
20.3%
净利率更高
CSW
高出66.4%
-62.0%
自由现金流更多
CSW
多$123.5M
$-100.8M
两年增速更快
RARE
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $233.0M | $207.3M |
| 净利润 | $10.3M | $-128.6M |
| 毛利率 | 39.7% | — |
| 营业利润率 | 7.4% | -54.7% |
| 净利率 | 4.4% | -62.0% |
| 营收同比 | 20.3% | 25.9% |
| 净利润同比 | -61.9% | 3.5% |
| 每股收益（稀释后） | $0.62 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSWRARE
| Q4 25 | $233.0M | $207.3M | ||
| Q3 25 | $277.0M | $159.9M | ||
| Q2 25 | $263.6M | $166.5M | ||
| Q1 25 | $230.5M | $139.3M | ||
| Q4 24 | $193.6M | $164.6M | ||
| Q3 24 | $227.9M | $139.5M | ||
| Q2 24 | $226.2M | $147.0M | ||
| Q1 24 | $210.9M | $108.8M |
净利润CSWRARE
| Q4 25 | $10.3M | $-128.6M | ||
| Q3 25 | $40.7M | $-180.4M | ||
| Q2 25 | $40.9M | $-115.0M | ||
| Q1 25 | $35.1M | $-151.1M | ||
| Q4 24 | $26.9M | $-133.2M | ||
| Q3 24 | $36.1M | $-133.5M | ||
| Q2 24 | $38.6M | $-131.6M | ||
| Q1 24 | $31.8M | $-170.7M |
毛利率CSWRARE
| Q4 25 | 39.7% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 43.8% | — | ||
| Q1 25 | 44.2% | — | ||
| Q4 24 | 41.4% | — | ||
| Q3 24 | 45.6% | — | ||
| Q2 24 | 47.5% | — | ||
| Q1 24 | 44.4% | — |
营业利润率CSWRARE
| Q4 25 | 7.4% | -54.7% | ||
| Q3 25 | 20.5% | -106.9% | ||
| Q2 25 | 20.8% | -64.8% | ||
| Q1 25 | 19.5% | -102.6% | ||
| Q4 24 | 15.3% | -74.3% | ||
| Q3 24 | 22.6% | -94.6% | ||
| Q2 24 | 24.3% | -79.1% | ||
| Q1 24 | 21.0% | -151.9% |
净利率CSWRARE
| Q4 25 | 4.4% | -62.0% | ||
| Q3 25 | 14.7% | -112.8% | ||
| Q2 25 | 15.5% | -69.0% | ||
| Q1 25 | 15.2% | -108.5% | ||
| Q4 24 | 13.9% | -80.9% | ||
| Q3 24 | 15.8% | -95.7% | ||
| Q2 24 | 17.1% | -89.5% | ||
| Q1 24 | 15.1% | -156.8% |
每股收益（稀释后）CSWRARE
| Q4 25 | $0.62 | $-1.28 | ||
| Q3 25 | $2.41 | $-1.81 | ||
| Q2 25 | $2.43 | $-1.17 | ||
| Q1 25 | $2.05 | $-1.57 | ||
| Q4 24 | $1.60 | $-1.34 | ||
| Q3 24 | $2.26 | $-1.40 | ||
| Q2 24 | $2.47 | $-1.52 | ||
| Q1 24 | $2.03 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.2M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $-80.0M |
| 总资产 | $2.3B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSWRARE
| Q4 25 | $40.2M | $421.0M | ||
| Q3 25 | $31.5M | $202.5M | ||
| Q2 25 | $38.0M | $176.3M | ||
| Q1 25 | $225.8M | $127.1M | ||
| Q4 24 | $213.8M | $174.0M | ||
| Q3 24 | $273.2M | $150.6M | ||
| Q2 24 | $18.9M | $480.7M | ||
| Q1 24 | $22.2M | $112.3M |
总债务CSWRARE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $800.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $166.0M | — |
股东权益CSWRARE
| Q4 25 | $1.1B | $-80.0M | ||
| Q3 25 | $1.1B | $9.2M | ||
| Q2 25 | $1.1B | $151.3M | ||
| Q1 25 | $1.1B | $144.2M | ||
| Q4 24 | $1.0B | $255.0M | ||
| Q3 24 | $1.0B | $346.8M | ||
| Q2 24 | $650.2M | $432.4M | ||
| Q1 24 | $615.7M | $140.3M |
总资产CSWRARE
| Q4 25 | $2.3B | $1.5B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.4B | $1.5B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.0B | $1.3B |
负债/权益比CSWRARE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $22.7M | $-100.8M |
| 自由现金流率自由现金流/营收 | 9.8% | -48.6% |
| 资本支出强度资本支出/营收 | 2.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.81× | — |
| 过去12个月自由现金流最近4个季度 | $162.0M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CSWRARE
| Q4 25 | $28.9M | $-99.8M | ||
| Q3 25 | $61.8M | $-91.4M | ||
| Q2 25 | $60.6M | $-108.3M | ||
| Q1 25 | $27.3M | $-166.5M | ||
| Q4 24 | $11.6M | $-79.3M | ||
| Q3 24 | $66.8M | $-67.0M | ||
| Q2 24 | $62.7M | $-77.0M | ||
| Q1 24 | $22.4M | $-190.7M |
自由现金流CSWRARE
| Q4 25 | $22.7M | $-100.8M | ||
| Q3 25 | $58.7M | $-92.7M | ||
| Q2 25 | $57.7M | $-110.7M | ||
| Q1 25 | $22.8M | $-167.8M | ||
| Q4 24 | $8.5M | $-79.5M | ||
| Q3 24 | $61.3M | $-68.6M | ||
| Q2 24 | $59.6M | $-79.0M | ||
| Q1 24 | $17.5M | $-193.9M |
自由现金流率CSWRARE
| Q4 25 | 9.8% | -48.6% | ||
| Q3 25 | 21.2% | -58.0% | ||
| Q2 25 | 21.9% | -66.5% | ||
| Q1 25 | 9.9% | -120.5% | ||
| Q4 24 | 4.4% | -48.3% | ||
| Q3 24 | 26.9% | -49.2% | ||
| Q2 24 | 26.3% | -53.7% | ||
| Q1 24 | 8.3% | -178.2% |
资本支出强度CSWRARE
| Q4 25 | 2.6% | 0.5% | ||
| Q3 25 | 1.1% | 0.8% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 2.0% | 1.0% | ||
| Q4 24 | 1.6% | 0.1% | ||
| Q3 24 | 2.4% | 1.2% | ||
| Q2 24 | 1.4% | 1.4% | ||
| Q1 24 | 2.3% | 3.0% |
现金转化率CSWRARE
| Q4 25 | 2.81× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.62× | — | ||
| Q1 24 | 0.71× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
